We further discovered that estrogen activates the Akt pathway in Brca1-deficient mammary tumor cells independent of ER, and that pharmaceutical inhibition of Akt activity suppresses EMT and cell proliferation preventing Brca1-deficient tumor progression. Here, AKT1 is linked to breast cancer.